To illustrate the efficacy of the SBAR (Subject, Background, Assessment, and Recommendation) framework, we considered a patient with non-valvular atrial fibrillation. Implantation of a device has been considered as the best treatment for our theoretical patient, so now it’s time to engage all the expertise such a procedure requires: an interventional cardiologist, a cardiovascular surgeon, a neurologist, and a hospitalist.
In addition, team workflows need to be designed, along with education and training of procedural and post-procedural staff. Once the true costs of the procedure are gathered and the reimbursement is understood, analysis of the product cost can be determined and negotiations with suppliers can begin. The conclusion should become a recommendation to senior leadership, who can hold all parties to key performance indicators that track cost and quality outcomes.
The new technology should then be reviewed in six to twelve months to determine whether changes are appropriate.
Download the Comprehensive Safe Start white paper written by TractManager’s value analysis experts, Dee Donatelli, Dr. Mark Kestner, Dr. Kristin Stitt, and Barry Dyer, and learn how to:
- Better assess the clinical, infrastructural, and financial impact of a technology.
- Foster more inclusive and effective value analysis decisions.
- Achieve measurable improvements in Quadruple Aim performance indicators.